Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Real Estate
  • Entertainment
  • Software
  • Concealed Carry
  • Non-profit
Washingtoner

Study Finds Lotus Vaping Technologies' Flavored E-Liquids Reduce Smokers' Cigarettes Per Day at Significantly Higher Rate Than Tobacco Flavor
Washingtoner/10239600

Trending...
  • OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
  • Applicants Sought for the Tacoma Arts Commission and the Tacoma Creates Advisory Board
  • City of Spokane Launches 'Emergency Streets' Pilot Program
A rigorous three-month longitudinal cohort study of several of flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

BOISE, Idaho - Washingtoner -- Lotus Vaping Technologies, LLC, a Boise, Idaho-based manufacturer of bottled e-liquids for use in electronic nicotine delivery systems ("ENDS") or e-cigarettes, announced today that a rigorous three-month longitudinal cohort study of several of its FreenomsTM branded flavored bottled e-liquids demonstrated that those flavors were significantly more effective at reducing cigarettes smoked per day than tobacco-flavored e-liquids.

The three-month study conducted from March 2023 to August 2023 involved 451 randomly assigned participants who were cigarette smokers, 221 of which were assigned to a control group that used only tobacco-flavored e-liquid, and 230 of which were assigned to a group that could use any of five different non-tobacco flavored bottled e-liquids, including Lotus's proprietary BluenomenomTM, StranomenonTM, X2 Cactus Jackfruit, and White Peach Raspberry flavors.

More on Washingtoner
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off
  • Fashion vs. Fascism - Because Democracy Should Always Be In Style

At the end of three months, the average number of cigarettes smoked per day ("CPD") by the tobacco-flavored control group was reduced from 12.51 to 9.54, for a 23.72% reduction, while for the flavored e-liquid group, the average CPD was reduced from 11.70 to 6.88, for a 41.25% reduction.  The reduction in cigarettes smoked per day was thus 73.9% greater for the flavored group than the tobacco-flavored group. The study results also demonstrated statistically significant differences between several of Lotus's flavored e-liquids when compared head-to-head against tobacco-flavored e-liquids with respect to CPD reduction.

Additionally, a full 14.3% of study participants in the flavored group had quit smoking cigarettes altogether by the end of the third month—a rate that is substantially higher than that typically reported for FDA-approved nicotine replacement therapy products (9.0%).

Lotus's Director of Sales, Mike Larsen stated, "We are very excited about these study results. This study demonstrates what users of our products have known anecdotally for a long time—flavored e-liquids are more effective than tobacco flavor at promoting cigarette smoking reduction and cessation. The FDA has been asking for this data—we hope it will now take it into consideration when reviewing our premarket tobacco product applications and grant our flavored products the marketing authorizations that they deserve."

More on Washingtoner
  • Lee Gunn IV Shares Lessons From 40 Years in the Courtroom on PodNumbra Podcast
  • Michael H. Kaplan Recognized for 17 Years on PHPA Workers' Compensation Panel and Advocacy for Professional Athletes
  • City of Spokane Announces New Tools, Resources to Support Fire Recovery and Rebuilding
  • Tacoma Residents Invited to Turn Recycled Glass Into Art Through New Pilot Program
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026

About Lotus Vaping Technologies, LLC – Creator of NomenonsTM E-Liquids

Established in 2013, Lotus is a leading manufacturer and wholesaler of premium e-liquids in the United States providing a diverse range of vapor products for sale to adult consumers that satisfy a wide variety of consumer preferences and serve as alternatives to combustible cigarettes. Lotus is committed to responsible manufacturing processes and utilizes only the highest standards in its e-liquid production.

Media Contact
Mike Larsen
mike@lotusecigs.com


Source: Lotus Vaping Technologies, LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Tacoma: Application for 2027 Community Arts Projects Funding Now Available
  • Haven Treatment Center Now In-Network Partnership with ComPsych, Expanding Access to Youth Health
  • Tacoma: OMWBE Certification 201 Workshop on September 28
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pebble Photo Booths Brings Modern Photo Experiences to Vancouver, Washington
  • Spokane: Flags at Half-Staff in Remembrance of 9/11 Victims
  • Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • City of Spokane Launches 'Emergency Streets' Pilot Program
  • Spokane: City Seeks Feedback on Future Land Use Map
  • Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
  • Longevity Academy Announces J.P. Medved of Longevity Advice as Next Guest in the Longevity Leaders
_catLbl0 _catLbl1

Popular on Washingtoner

  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support - 239
  • Diginyze eCommerce ERP Module Creates Single Source of Truth for Enterprise Operations - 156
  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 138
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 130
  • Tacoma: Applications Now Being Accepted for a Position on the Planning Commission - 127
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 127
  • DuoKey launches the World's First Agentic Crypto Agility Platform - 117
  • Tacoma: Hylebos Bridge Closed Today for Maintenance Work - 115
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified

Similar on Washingtoner

  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • Haven Treatment Center Now In-Network Partnership with ComPsych, Expanding Access to Youth Health
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Longevity Academy Announces J.P. Medved of Longevity Advice as Next Guest in the Longevity Leaders
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute